Sebastian Unizony is a Rheumatology/Immunology physician affiliated with Harvard University. OpenAlex indexes 112 publications with 6,141 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Rheumatology Department, Bulfinch 165
Boston, MA 021142621
Telephone
617-726-2000Registry record last updated 8 Jun 2011.
Clinical trials
- CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Sponsor: Marcela V. Maus, M.D.,Ph.D.
- Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20242 payments
- AbbVie Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.5%Interleukin-6 Receptor Antagonist11.4%Actemra Actpen78%Actemra23%Part D<11 patientsFolate Analog Metabolic Inhibitor11.2%Methotrexate100%Part D≥47 patients+ 5 more classes in this area
Nervous system
21.4%Gabapentinoids8%Gabapentin83%Pregabalin17%Part D<11 patientsSNRI6.7%Duloxetine Hcl78%Venlafaxine Hcl Er22%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21.2%Corticosteroid19%Prednisone100%Part D≥105 patientsAntidiarrheal microorganisms2.2%Folic Acid100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment
Annals of the Rheumatic Diseases
2025 - Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper
New England Journal of Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Sarah Fortune, MD
Harvard University
Rochelle Walensky, MD
Harvard University
Stephen Gomperts, MD
Harvard University
Yakir Levin, MD, PhD
Harvard University
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”